<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872206</url>
  </required_header>
  <id_info>
    <org_study_id>HPN536-2001</org_study_id>
    <nct_id>NCT03872206</nct_id>
  </id_info>
  <brief_title>Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression</brief_title>
  <official_title>A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harpoon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harpoon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability
      and PK in patients with advanced cancers associated with mesothelin expression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess initial safety and determination of recommended Phase 2 dose: Dose limiting toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Dose limiting toxicity measured by adverse events and serious adverse events will be reviewed by dose level by the Safety Oversight Committee and will result in a recommended Phase 2 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of HPN536 at the recommended Phase 2 dose: overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate overall response rate (ORR) as assessed by RECIST</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Advanced Cancers Associated With Mesothelin Expression</condition>
  <arm_group>
    <arm_group_label>HPN536-2001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or pancreatic adenocarcinoma. HPN536 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.
Part 2 (Dose Expansion):
Group 1: Eligible patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Group 2: Eligible patients with pancreatic adenocarcinoma.
Group 3: Eligible patients with mesothelioma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPN536</intervention_name>
    <description>Dose escalation: HPN536 will be administered once weekly via IV infusion Dose expansion: HPN536 will be administered at the RP2D once weekly via IV infusion</description>
    <arm_group_label>HPN536-2001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patients ≥18 years of age

          2. One of the following progressive advanced or metastatic cancers:

               1. Epithelial ovarian, fallopian tube, or primary peritoneal cancer (Part 1 and Part
                  2, Group 1 only) that is platinum refractory or platinum resistant

               2. Pancreatic adenocarcinoma (Part 1 and Part 2, Group 2 only) that is locally
                  advanced, and now with progressive disease on or after front-line treatment

               3. Malignant mesothelioma with epithelioid histology, pleural or primary peritoneal
                  (Part 2, Group 3 only) that is progressive disease following frontline
                  platinum-based chemotherapy

          3. For Part 2 only - Measurable disease according to RECIST v1.1 for patients with
             epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic
             adenocarcinoma, and peritoneal mesothelioma, and mRECIST v1.1 for patients with
             pleural mesothelioma

          4. Available archival tissue sample or fresh biopsy tissue sample must be obtained prior
             to enrollment

          5. For patients previously treated with systemic chemotherapy, targeted therapy,
             immunotherapy, or treatment with an investigational anticancer agent, discontinuation
             must have occurred ≥2 weeks, or at least 5 half-lives, whichever is longer, prior to
             start of study drug. The maximum washout period will not exceed 4 weeks

          6. ECOG performance status of 0 or 1

          7. Adequate bone marrow function, including:

               1. Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L

               2. Platelets ≥100,000/mm3 or ≥100 x 109/L

               3. Hemoglobin (Hgb) ≥10 g/dL

          8. Adequate renal function, including estimated creatinine clearance ≥30 mL/min

          9. Adequate liver function, including:

               1. Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has
                  documented Gilbert syndrome in which case the maximum total serum bilirubin
                  should be &lt;5 mg/dL

               2. Aspartate and alanine transaminase (AST and ALT) ≤2.5 x ULN or AST/ALT ≤5 x ULN
                  for patients with liver metastases

         10. Serum albumin as follows:

               1. ≥30 mg/mL for patients with epithelial ovarian cancer, fallopian tube cancer,
                  primary peritoneal cancer, or mesothelioma

               2. Within normal limits for patients with pancreatic adenocarcinoma

         11. Patients with pancreatic adenocarcinoma: C-reactive protein (CRP) within normal limits

        Key Exclusion Criteria:

          1. Previously treated or current brain metastases. Note: Patients with previously treated
             brain metastases may participate provided they are clinically stable for at least 4
             weeks prior to study entry and have no evidence of new or enlarging brain metastases

          2. Concurrent treatment with anti- TNFα therapies, systemic corticosteroids, or other
             immune suppressive drugs within the 2 weeks prior to Screening

          3. Patients with pancreatic adenocarcinoma: Any ascites within 1 month prior to screening

          4. History of or known or suspected autoimmune disease

          5. History of clinically significant cardiovascular disease

          6. Pulmonary, hematologic, renal, hepatic, gastrointestinal, neurological or psychiatric
             disease that would limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harpoon Therapeutics</last_name>
    <phone>1-650-689-1047</phone>
    <email>HPN5362001@harpoontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ahn, MD</last_name>
      <phone>480-342-2000</phone>
      <email>Ahn.Daniel@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-794-6500</phone>
      <email>LYonemoto@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Colon-Otero, MD</last_name>
      <phone>904-953-2000</phone>
      <email>Gcolonotero@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Wahner Hendrickson, MD</last_name>
      <phone>507-284-2511</phone>
      <email>WahnerHendrickson.Andrea@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Ezell</last_name>
      <phone>314-273-3899</phone>
      <email>Casey.ezell@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Shepard, MD</last_name>
      <phone>216-445-5670</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephenson Cancer Center</last_name>
      <phone>405-271-8778</phone>
      <email>PhaseI-Referrals@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Institute</last_name>
    </contact>
    <contact_backup>
      <phone>1-844-482-4812</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Crowley Cancer Research</last_name>
      <phone>972-566-3000</phone>
      <email>Referral@MaryCrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

